International Development Association. See World Bank

International Dispensary Association, 40

International Federation of Pharmaceutical Manufacturers Associations (IFPMA), 47, 303

International Finance Corporation, 12

International funding, 2

International Nonproprietary Names (INNs), 40

International organizations and health

programs, 46–52, 85.

See also specific organizations

IOM. See Institute of Medicine

IPT. See Intermittent preventive therapy

IPTc. See Intermittent preventive therapy, children

IPTi. See Intermittent preventive therapy, infants

IPTp. See Intermittent preventive therapy, pregnant women

Ireland, 105

Irian Jaya, 231

IRS. See Insecticide spraying, indoor residential

Italy, 105, 126, 131, 213

Iteso, 323

ITNs. See Insecticide-treated nets

J

Jacobus Pharmaceuticals, 309

Japan, 105

Jaundice, 149

Java, 130, 131

Jomaa Pharmaceuticals, 308

K

Kafue, Zambia, 44

Karen, Thailand, 227

Kdr. See Knock-down resistance

Kenya

ACT, evidence base, 264

Anopheles gambiae, 202

antimalarial drug resistance, 271

azithromycin clinical trials, 310

childhood mortality, 173

chloroquine-resistant P. falciparum, 132, 235

climate change, 231

drug policy, 235

health care spending, 97, 98

home treatment, 318

hospital-based studies, 177

IPTi trials, 219

Kisumu, 207

malaria early warning system, 233

malaria treatment survey, 33

migration, 232

Ministry of Health, 235, 320

pharmaceuticals from, 36

productivity costs, 188–189

school-based education, 232

total direct and indirect costs, 187

training, 320-321

trials, 203–206, 209, 224

urban malaria, 230

Kenya Medical Research Institute, 224, 235

Kilombero, Tanzania, 94

Kinshasa, Congo, 177

Kisumu, Kenya, 207

Knock-down resistance (kdr), 202

Koch, Robert, 213

Konkola Copper Mines, 229

Korea, 157, 307

KwaZulu Natal, South Africa

ACT as first-line therapy, 229, 236

DDT house spraying, 207

drug policy, 235

epidemic, 172

Ingwavuma district, 214

malaria control, 11, 14, 64

morbidity and mortality, 214–215

L

Labeling and instructions, 317–318

Lagos, Nigeria, 169, 317

Laos, 101, 236, 280, 318

Lapdap, 22n. 1, 292, 307

Lariam, 306

Larvivorous fish, 211

Late clinical failures (LCF), 279

Laveran, Charles Louis Alphonse, 127–128

Ledger, Charles, 130

Lee, J.W., 120

Lesotho, 98

Liberia, 98

LICA Pharmaceuticals, 309

Front Matter (R1-R20)

Executive Summary (1-16)

Part 1: A Response to the Current Crisis1 Malaria Today (17-60)

2 The Cost and Cost-Effectiveness of Antimalarial Drugs (61-78)

3 The Case for a Global Subsidy of Antimalarial Drugs (79-111)

4 An International System for Procuring Anitmalarial Drugs (112-122)

Part 2: Malaria Basics5 A Brief History of Malaria (123-135)

6 The Parasite, the Mosquito, and the Disease (136-167)

7 The Human and Economic Burden of Malaria (168-196)

8 Malaria Control (197-251)

9 Antimalarial Drugs and Drug Resistance (252-298)

Part 3: Advancing Toward Better Malaria Control10 Research and Development for New Antimalarial Drugs (299-311)

11 Maximizing the Effective Use of Antimalarial Drugs (312-328)

Acronyms and Abbreviations (329-333)

Glossary (334-346)

Index (347-364)